Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study

We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Seitman, David, Fallon, Joseph, Kimmels, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Endourology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165545/
https://www.ncbi.nlm.nih.gov/pubmed/34094874
http://dx.doi.org/10.1016/j.eucr.2021.101714
_version_ 1783701344919486464
author Seitman, David
Fallon, Joseph
Kimmels, Barry
author_facet Seitman, David
Fallon, Joseph
Kimmels, Barry
author_sort Seitman, David
collection PubMed
description We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.
format Online
Article
Text
id pubmed-8165545
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81655452021-06-05 Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study Seitman, David Fallon, Joseph Kimmels, Barry Urol Case Rep Endourology We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months. Elsevier 2021-05-20 /pmc/articles/PMC8165545/ /pubmed/34094874 http://dx.doi.org/10.1016/j.eucr.2021.101714 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Endourology
Seitman, David
Fallon, Joseph
Kimmels, Barry
Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_full Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_fullStr Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_full_unstemmed Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_short Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_sort testosterone therapy with testopel® and the esoterix laboratory assay: a case study
topic Endourology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165545/
https://www.ncbi.nlm.nih.gov/pubmed/34094874
http://dx.doi.org/10.1016/j.eucr.2021.101714
work_keys_str_mv AT seitmandavid testosteronetherapywithtestopelandtheesoterixlaboratoryassayacasestudy
AT fallonjoseph testosteronetherapywithtestopelandtheesoterixlaboratoryassayacasestudy
AT kimmelsbarry testosteronetherapywithtestopelandtheesoterixlaboratoryassayacasestudy

Ejemplares similares